Skip to content

Dyne Therapeutics, Inc. DYN Free cash flow yield

Free cash flow yield at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-11.6%+15.9pp
Arrowhead Research logo
Arrowhead ResearchARWR
0.5%+0.3pp
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-4.4%-0.8pp
PTC Therapeutics logo
PTC TherapeuticsPTCT
17.2%+14.6pp
Scholar Rock logo
Scholar RockSRRK
-5.4%-1.2pp
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
6.9%-2.2pp

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.35B+153%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Calculated from Dyne Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s free cash flow yield?
Dyne Therapeutics, Inc. (DYN) reported free cash flow yield of -14.8% in Q1 2026.
How has Dyne Therapeutics, Inc.'s free cash flow yield changed year-over-year?
Dyne Therapeutics, Inc.'s free cash flow yield increased by 45.7% year-over-year, from -27.3% to -14.8%.
What is the long-term trend for Dyne Therapeutics, Inc.'s free cash flow yield?
Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s free cash flow yield has grown at a 22.3% compound annual growth rate (CAGR), from -4.6% to -12.6%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.